<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821053</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-1-13</org_study_id>
    <nct_id>NCT01821053</nct_id>
  </id_info>
  <brief_title>Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus</brief_title>
  <official_title>Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A tonic active epithelial Na+ channel (ENaC) in pre-eclampsia (PE) escaped normal hormonal&#xD;
      control may offer an attractive explanatory model for the pathophysiology of established PE.&#xD;
      The channel is activated by plasmin. Microalbuminuria predicts the development of&#xD;
      pre-eclampsia in pregnant patients with pregestational diabetes type 1. The investigators&#xD;
      hypothesize that urine-plasmin excreted in the kidneys, when proteinuria occurs, could be the&#xD;
      cause. The investigators want to test the correlation between measurable plasmin/plasminogen&#xD;
      in the urine early in pregnancy and the development of preeclampsia in pregnant patients with&#xD;
      type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study aim and hypothesis:&#xD;
&#xD;
      Aim:&#xD;
&#xD;
      To test whether there is a measurable correlation between plasmin/plasminogen, abnormally&#xD;
      excreted in the kidneys, and the development of pre-eclampsia in pregnant women with Type 1&#xD;
      diabetes.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      1. The amount of proteases ( plasmin/plasminogen ), excreted in urine, predicts development&#xD;
      of preeclampsia in pregnant patients with type 1 diabetes.&#xD;
&#xD;
      If a correlation between excreted plasmin/plasminogen, in urine, in patients with type 1&#xD;
      diabetes and development of preeclampsia, are seen, proteases might be used as a marker for&#xD;
      pre-eclampsia in this group of patients. Prospectively perhaps also as a marker for disease&#xD;
      severity.&#xD;
&#xD;
      In these high risk groups it is possible that outpatient visits could be optimized and thus&#xD;
      lower the amount of preterm births.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      The study is an observational, longitudinal - prospective study. Women with pregestational&#xD;
      type 1 diabetes are included when they show up for their first outpatient pregnancy visit&#xD;
      around pregnancy week 9.&#xD;
&#xD;
      Selection of patients:&#xD;
&#xD;
      Patients are selected from Gynecological- obstetric department, Aarhus University hospital -&#xD;
      Skejby, and Gynecological- Obstetric department, Odense University Hospital. To be included&#xD;
      they must be singleton-pregnant, have turned 18 years and have Type 1 diabetes.&#xD;
&#xD;
      Background information:&#xD;
&#xD;
      Date of birth, sex, weight, height, BMI, smoking status, current medical treatment, duration&#xD;
      of diabetes and parity are registered.&#xD;
&#xD;
      Length of gestation, placental weight, way of delivery (natural birth or cesarean section),&#xD;
      umbilical cord pH, apgar score and infant weight are registered post-partum.&#xD;
&#xD;
      Effect variables:&#xD;
&#xD;
      Clinical:&#xD;
&#xD;
      Weight, height, BMI, smoking status, microalbuminuria/proteinuria. Blood pressure (systolic,&#xD;
      diastolic, mean arterial pressure). Weight of placenta.&#xD;
&#xD;
      Blood test measurements:&#xD;
&#xD;
      Se-creatinine, p-Na+, p-K+. P-plasminogen, P-albumin, Aldosterone.&#xD;
&#xD;
      Measurements in 50 ml &quot;spot urine&quot;:&#xD;
&#xD;
      Plasmin, plasminogen, ENaC peptide fragment (analyses in location of development,)&#xD;
      Proteolytic activity, Prostatin, Creatinine, Na+, K+, Aldosterone, Albumin&#xD;
&#xD;
      Study process:&#xD;
&#xD;
      Collection of blood- and spot-urine samples:&#xD;
&#xD;
      Urine-samples are collected in pregnancy week 9-14. Blood pressure is measured. Samples and&#xD;
      blood-pressures are re-collected in pregnancy-week 20, 28,32, 36 and perhaps 38.&#xD;
&#xD;
      Following outcomes are observed: Development of preeclampsia, defined by hypertension ( &gt;&#xD;
      140/90 mmHg), and proteinuria ( &gt;0,3 g/24 hour). Preterm delivery and light for gestational&#xD;
      age.&#xD;
&#xD;
      Data- analysis methods:&#xD;
&#xD;
      This is an observational longitudinal-prospective study which includes approximately 130&#xD;
      pregnant patients with Type 1 diabetes. Patients are included from Skejby and Odense&#xD;
      University Hospitals in cooperation.&#xD;
&#xD;
      Results are evaluated statistically by uni - and multivariate logistic regression analysis.&#xD;
&#xD;
      Population size estimation:&#xD;
&#xD;
      Similar (Danish) observational prospective studies on urine- biomarkers (including albumin)&#xD;
      ability to predict preeclampsia/preterm delivery, in patients with pre-gestational type 1&#xD;
      diabetes, have been made. They achieved high significance data with spot-samples of 130 -170&#xD;
      patients. With the participation of two centers it seems realistic and adequately to include&#xD;
      130 patients within the settings of a Ph. D. study. Every year an amount of 50-60 patients&#xD;
      are seen in the outpatient ward at Skejby- and Odense University Hospitals (in all&#xD;
      approximately 100-120 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>preeclampsia</measure>
    <time_frame>3 years</time_frame>
    <description>The development of preeclampsia, defined by hypertension ( &gt; 140/90 mmHg) and proteinuria ( &gt;0,3 g/24 hour).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>preterm delivery</measure>
    <time_frame>3 years</time_frame>
    <description>post-partum registration of preterm delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>light for gestational age</measure>
    <time_frame>3 years</time_frame>
    <description>post-partum registration of &quot;light for gestational age&quot;</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">85</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>pregestational type 1 diabetes</arm_group_label>
    <description>It is an observational study. No intervention is made.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood serum plasma urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women with pregestational type 1 diabtes are included when they show up for their&#xD;
        first outpatient pregnancy visit around the 9th weeks gestation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  singleton gravida,&#xD;
&#xD;
          -  over 18 years,&#xD;
&#xD;
          -  Pregestational type 1 diabetes. Gestation week 8-14.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Possible comorbidity like systemic lupus erythematosus (SLE), hypertension and&#xD;
             rheumatoid arthritis.&#xD;
&#xD;
          2. Organic or systematic diseases with clinical relevance ( ex. Malignity)&#xD;
&#xD;
        However it has to be mentioned that quite some patients have thyroid diseases with no&#xD;
        impact on the kidneys nor hypertension. It is therefore possible to include these patients.&#xD;
&#xD;
        Thyroid diseases are NOT a reason for exclusion.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boye L. Jensen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>cardiovascular and renal research department, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynelogical Obstetrical Department</name>
      <address>
        <city>Skejby</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Lise Hald Nielsen</investigator_full_name>
    <investigator_title>doctor, Ph.D student</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Pregestational Type 1 diabetes</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>proteinuria</keyword>
  <keyword>plasminogen</keyword>
  <keyword>plasmin</keyword>
  <keyword>renin</keyword>
  <keyword>aldosterone</keyword>
  <keyword>angiotensin</keyword>
  <keyword>epithelial sodium channel</keyword>
  <keyword>ENaC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

